Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1695
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded127    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2019  |  Volume : 56  |  Issue : 3  |  Page : 274-275

TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study

1 Department of Medical Oncology, Fortis Hospital, Bengaluru, Karnataka, India
2 Department of Clinical Genomics and Bioinformatics, Positive Bioscience, Mumbai, Maharashtra, India

Correspondence Address:
Linu A Jacob
Department of Medical Oncology, Fortis Hospital, Bengaluru, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_732_18

Rights and Permissions

We report a case of a 67-year-old man with pazopanib-resistant metastatic renal cell carcinoma (mRCC) who showed an exceptional response to everolimus. Furthermore, this patient had TSC1 and TSC2 mutations. Only a subset of patients with mRCC respond to mTOR inhibitors and emerging evidences indicate that TSC1 and TSC2 mutations could be markers of response to mTOR inhibition. The current case study supports these accruing evidences.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow